Canthera Discovery Type I interferon activator

Canthera Discovery is developing an undisclosed small molecule designed to activate the Type I interferon (IFN) signaling pathway for the treatment of multiple cancers. Type I interferons, such as IFN-α and IFN-β, are essential components of the innate immune response that facilitate the maturation of dendritic cells and the activation of cytotoxic T cells. By triggering this pathway, the drug aims to enhance the immune system's ability to recognize and destroy tumor cells, potentially converting 'cold' tumors into 'hot' tumors that are more responsive to checkpoint inhibitors and other immunotherapies. While Canthera Discovery has specific programs targeting STING and ENPP1, this program is listed as a general Type I interferon activator with an undisclosed molecular target.